title: HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy.
authors: Emanuele
authors: E
authors: Nicastri
authors: Luca
authors: L
authors: Dori
authors: Anna R
authors: AR
authors: Buonomini
authors: Chiara
authors: C
authors: Tommasi
authors: Pasquale
authors: P
authors: De Nardo
authors: Rita
authors: R
authors: Bellagamba
authors: Angela
authors: A
authors: Corpolongo
authors: Marco
authors: M
authors: Montano
authors: Pasquale
authors: P
authors: Sordillo
authors: Antonio
authors: A
authors: Volpi
authors: Loredana
authors: L
authors: Sarmati
authors: Massimo
authors: M
authors: Andreoni
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D057134:Antibodies, Neutralizing / Q000187:drug effects / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D008297:Male; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D057134:Antibodies, Neutralizing